Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 1
2005 2
2006 1
2007 2
2008 5
2009 2
2010 3
2011 5
2012 4
2013 3
2014 2
2015 4
2016 4
2017 4
2018 4
2019 9
2020 15
2021 16
2022 24
2023 18
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

113 results

Results by year

Filters applied: . Clear all
Page 1
Real-world survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for nonmetastatic castration-resistant prostate cancer.
Tsujino T, Tokushige S, Komura K, Fukuokaya W, Adachi T, Hirasawa Y, Hashimoto T, Yoshizawa A, Saruta M, Ohno T, Nakamori K, Maenosono R, Nishimura K, Yamazaki S, Uchimoto T, Yanagisawa T, Mori K, Urabe F, Tsuzuki S, Iwatani K, Yamamoto S, Takahara K, Inamoto T, Kimura T, Ohno Y, Shiroki R, Azuma H. Tsujino T, et al. Among authors: shiroki r. Cancer Med. 2023 Oct;12(19):19414-19422. doi: 10.1002/cam4.6536. Epub 2023 Sep 14. Cancer Med. 2023. PMID: 37706578 Free PMC article.
Boron neutron capture therapy for urological cancers.
Takahara K, Miyatake SI, Azuma H, Shiroki R. Takahara K, et al. Among authors: shiroki r. Int J Urol. 2022 Jul;29(7):610-616. doi: 10.1111/iju.14855. Epub 2022 Mar 3. Int J Urol. 2022. PMID: 35240726 Review.
Re-challenging chemotherapy after pembrolizumab in platinum-refractory urothelial carcinoma.
Uchimoto T, Fukushima T, Komura K, Fukuokaya W, Adachi T, Hashimoto T, Yoshizawa A, Nakamura K, Yano Y, Nishimura K, Nishio K, Nakamori K, Iwatani K, Yamamoto S, Urabe F, Mori K, Yanagisawa T, Tsuduki S, Takahara K, Inamoto T, Miki J, Kimura T, Ohno Y, Shiroki R, Egawa S, Azuma H. Uchimoto T, et al. Among authors: shiroki r. BJU Int. 2023 Apr;131(4):477-485. doi: 10.1111/bju.15893. Epub 2022 Sep 26. BJU Int. 2023. PMID: 36098556
Real world evidence of enfortumab vedotin in patients with advanced urothelial cancer: A multicenter observational study.
Fukuokaya W, Koike Y, Yata Y, Komura K, Uchimoto T, Tsujino T, Saruta M, Takahara K, Fujita K, Minami T, Adachi T, Hirasawa Y, Hashimoto T, Ohno Y, Uemura H, Shiroki R, Azuma H, Kimura T. Fukuokaya W, et al. Among authors: shiroki r. Int J Urol. 2024 Apr;31(4):342-347. doi: 10.1111/iju.15368. Epub 2023 Dec 19. Int J Urol. 2024. PMID: 38113343
113 results